We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Testing Medicines After Brexit: Upholding High QC Standards for Pharmaceuticals

Article   Oct 22, 2019 | By Peter Morgan, Technical Product Specialist, Elementar UK

 
Testing Medicines After Brexit: Upholding High QC Standards for Pharmaceuticals
 
 
 

RELATED ARTICLES

Key Themes and Conversations From the First Lab of the Future Congress

Article

What do we mean by lab of the future? What innovations are required to get there? These are the key themes explored by this year's Lab of the Future Congress, summarized in this article.

READ MORE

Could Cannabinoids Be Used To Treat PTSD?

Article

Effective treatments for post-traumatic stress disorder (PTSD) have proved extremely elusive to researchers. For some, the legalisation of cannabis could present an opportunity to develop new therapies for PTSD.We talked to Allied Corp’s CEO Calum Hughes about cannabis’s potential for PTSD therapeutics.

READ MORE

The Promise of In Vitro 3D Organoid Models: Meeting the ADME-Tox Testing Needs of the Pharmaceutical Industry

Article

For many years, biologists have relied on in vitro 2-dimensional (2D) cell culture models to perform preclinical ADME-Tox assays. While these models are useful, they are limited in their translatability to drug metabolism and toxicity in humans. Recently, in vitro 3D organoid models that more closely mimic human biological systems have shown promise in supporting ADME-Tox studies in the early stages of drug discovery.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE